View printer-friendly version

ResApp Health Limited (ASX: RAP), the developer of smartphone medical applications for the diagnosis and management of respiratory disease, today announced that it is planning to conduct a clinical study with the Massachusetts General Hospital (MGH) for the ResAppDx US paediatric study. The MGH is a 1,000-bed academic medical centre located in Boston, Massachusetts. Each year, the MGH admits more than 50,000 patients, delivers nearly 4,000 babies and records 1.5 million outpatient visits, including more than 100,000 Emergency Department visits. In 2015, the MGH topped the Nature Index list of health care organizations for most publications in leading scientific journals. The MGH also has always been among the top few hospitals each year on the U.S. News & World Report list of “America’s Best Hospitals.”

“We are very pleased to be working with MGH, one of the most prestigious hospitals in the US,” said Tony Keating, Managing Director and CEO of ResApp. “Working with MGH will allow us to enrol large numbers of patients quickly and provide the highest quality clinical results for our FDA de novo submission.”

Data from the study will again be analysed by The University of Queensland team led by Associate Professor Udantha Abeyratne.

– ENDS –

About ResApp Health Limited
ResApp Health Limited (ASX: RAP) is a digital health company developing smartphone applications for the diagnosis and management of respiratory disease. The technology is based on machine learning algorithms that use sound alone to diagnose and measure the severity of respiratory conditions without the need for additional hardware. The algorithms were initially developed by The University of Queensland with funding from the Bill and Melinda Gates Foundation. ResApp has both adult and paediatric clinical studies underway with preliminary results demonstrating accurate diagnosis of pneumonia, asthma/viral wheeze, bronchiolitis, croup and upper respiratory tract infections in children as well as chronic obstructive pulmonary disease, asthma and pneumonia in adults. Markets for ResApp’s technology include telehealth use through partnerships with telehealth service providers, emergency department and regular clinic use by healthcare providers, at-home use by consumers and working with global aid and humanitarian organisations to deliver tools for the developing world.

For more information on ResApp, visit

Dr Tony Keating
CEO and Managing Director
+61 430 180 659

Brian Leedman
VP, Corporate Affairs
+61 412 281 780

ResApp Logo White

ResApp Health Limited
ABN 51 094 468 318
Level 12, 100 Creek St,
Brisbane, QLD 4000, Australia

Follow Us

© 2022 ResApp Health Limited. All rights reserved.